



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Gabriel Herrero-Beaumont
✉ gherrero@fjd.es

†These authors have contributed
equally to this work and share
first authorship

RECEIVED 28 November 2023
ACCEPTED 29 November 2023
PUBLISHED 06 December 2023

CITATION

Medina JP, Bermejo-Álvarez I,
Pérez-Baos S, Yáñez R,
Fernández-García M, García-Olmo D,
Mediero A, Herrero-Beaumont G and
Largo R (2023) Corrigendum: MSC therapy
ameliorates experimental gouty arthritis
hinting an early COX-2 induction.
Front. Immunol. 14:1345777.
doi: 10.3389/fimmu.2023.1345777

COPYRIGHT

© 2023 Medina, Bermejo-Álvarez,
Pérez-Baos, Yáñez, Fernández-García,
García-Olmo, Mediero, Herrero-Beaumont
and Largo. This is an open-access article
distributed under the terms of the [Creative
Commons Attribution License \(CC BY\)](#). The
use, distribution or reproduction in other
forums is permitted, provided the original
author(s) and the copyright owner(s) are
credited and that the original publication in
this journal is cited, in accordance with
accepted academic practice. No use,
distribution or reproduction is permitted
which does not comply with these terms.

Corrigendum: MSC therapy ameliorates experimental gouty arthritis hinting an early COX-2 induction

Juan Pablo Medina^{1†}, Ismael Bermejo-Álvarez^{1†},
Sandra Pérez-Baos¹, Rosa Yáñez^{2,3}, María Fernández-García^{2,3},
Damián García-Olmo^{4,5,6}, Aránzazu Mediero¹,
Gabriel Herrero-Beaumont^{1*} and Raquel Largo¹

¹Bone and Joint Research Unit, Rheumatology Dept, IIS-Fundación Jiménez Díaz Universidad Autónoma de Madrid (UAM), Madrid, Spain, ²Hematopoietic Innovative Therapies Division, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT) and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBER-ER), Madrid, Spain, ³Advanced Therapies Dept, IIS-Fundación Jiménez Díaz UAM, Madrid, Spain, ⁴New Therapies Laboratory, IIS-Fundación Jiménez Díaz UAM, Madrid, Spain, ⁵Department of Surgery, Fundación Jiménez Díaz University Hospital, Madrid, Spain, ⁶Department of Surgery, School of Medicine UAM, Madrid, Spain

KEYWORDS

mesenchymal stem cells (MSCs), innate inflammation, macrophage, polarization, inflammasome, prostaglandin E2, COX-2

A Corrigendum on

MSC therapy ameliorates experimental gouty arthritis hinting an early COX-2 induction

by Medina JP, Bermejo-Álvarez I, Pérez-Baos S, Yáñez R, Fernández-García M, García-Olmo D, Mediero A, Herrero-Beaumont G and Largo R (2023). *Front. Immunol.* 14:1193179. doi: 10.3389/fimmu.2023.1193179

In the published article, there was an error in the Funding statement. The funding statement was displayed as “This study was supported by research grants from the Instituto de Salud Carlos III (PIE15/00048; PI15/00770; PI18/00261; PI20/00349; PI22/00352), co-funded by Fondo Europeo de Desarrollo Regional (FEDER).” The correct statement is “This study was supported by research grants from the Instituto de Salud Carlos III (PIE15/00048; PI15/00770; PI18/00261; PI20/00349; PI22/00352), co-funded by the European Union.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.